The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 531 participants.
Also called NCT02059187
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 531 participants
- Sponsor
- Registry
-
NCT02059187 -
2012-003478-19
-
- Other papers using this trial's data
- Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT02059187. Randomized; no masking; primary purpose treatment. Start 2014-02-11 (actual); primary completion 2015-03-11 (actual). Results posted on 2017-03-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- MK-1293
- Intervention (Drug)
- Lantus™
- Intervention (Drug)
- Prandial insulin
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct02059187- Content hash
44edb42d512a2ef3ac09ec9582091a1a88db0e9293769a99787cc2ea7e688fba